KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Asset Writedowns and Impairment (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Asset Writedowns and Impairment for 14 consecutive years, with $1.3 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Asset Writedowns and Impairment changed N/A year-over-year to $1.3 million, compared with a TTM value of $2.5 million through Mar 2025, changed N/A, and an annual FY2024 reading of $1.3 million, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $1.3 million for Q1 2025 at TherapeuticsMD, up from $7000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.3 million in Q2 2024 and bottomed at -$540000.0 in Q4 2021.
  • Average Asset Writedowns and Impairment over 5 years is $313000.0, with a median of $222500.0 recorded in 2021.
  • Peak annual rise in Asset Writedowns and Impairment hit 287.57% in 2021, while the deepest fall reached 208.0% in 2021.
  • Year by year, Asset Writedowns and Impairment stood at -$540000.0 in 2021, then skyrocketed by 149.63% to $268000.0 in 2022, then tumbled by 77.99% to $59000.0 in 2023, then tumbled by 88.14% to $7000.0 in 2024, then soared by 17914.29% to $1.3 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for TXMD at $1.3 million in Q1 2025, $7000.0 in Q4 2024, and $1.3 million in Q2 2024.